Targeted therapies for lung cancer: how did the game begin? - Wikidata - wikimedia - TriplyDB

Targeted therapies for lung cancer: how did the game begin?

Targeted therapies for lung cancer: how did the game begin?

http://www.wikidata.org/entity/Q42431459

about

Independent and core pathways in oncogenic KRAS signaling.

P2860

Q40968374-25399906-8784-4D9C-A181-E55177747C0C

P2860

Targeted therapies for lung cancer: how did the game begin?

http://www.wikidata.org/entity/Q42431459

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Targeted therapies for lung cancer: how did the game begin?

@en

Targeted therapies for lung cancer: how did the game begin?

@nl

type

label

Targeted therapies for lung cancer: how did the game begin?

@en

Targeted therapies for lung cancer: how did the game begin?

@nl

prefLabel

Targeted therapies for lung cancer: how did the game begin?

@en

Targeted therapies for lung cancer: how did the game begin?

@nl

P1433

Q42431459-3D0CD161-FCC7-4D7B-B8BF-EC0F5710E1D7

P1476

Q42431459-E4A20CF2-FD7F-4273-BC1A-161B4416786A

P2093

Q42431459-2EE6E237-D16D-4928-B496-4D8B778F57F0

Q42431459-8FF04DF8-1EC0-4338-B8EF-174552A27C7B

P2860

Q42431459-0ED75BB1-9C8C-44B6-9544-0AFC8AC8A18A

Q42431459-2000E2CC-C9E8-4052-A39E-A8F42507BA54

Q42431459-359EF897-51FA-4BDC-B1A1-613F8B75EC38

Q42431459-3AA79992-045B-439B-838C-95394BCDC8C0

Q42431459-3D19D72B-AF98-4AA6-A347-FA8BF0D11332

Q42431459-422E3D79-CED5-4F40-89BF-4CB4CCB1C533

Q42431459-616FA189-0623-45AB-8A44-45CCE1C8C1B4

Q42431459-9F106820-92F7-4C50-8C6F-0D92293AC99D

Q42431459-DD7BCE6C-2AF8-4998-814A-AFC4ECB98FA3

Q42431459-EB43AD28-1B4B-4B70-AC10-D8FE9B160FA4

P304

Q42431459-B662602A-FA8B-4884-A6A1-2AEB126554CB

P31

Q42431459-276564C1-AFAC-4515-BCCB-741DFCDBE7F5

P356

Q42431459-3B9CAC17-5EF6-4D52-90A8-83073B72197D

P433

Q42431459-05D9456B-1C15-4303-BDB3-F2C9922B1C5A

P478

Q42431459-824D141D-ADBC-4736-8C1D-B9C503D3FB52

P50

Q42431459-E76330A3-318A-4161-9B79-D1917CE8BED6

P577

Q42431459-D997CBEF-8658-4622-A0A0-1564062E21BD

P698

Q42431459-24BF81A3-F52D-4CCD-A7C5-32D3D831AF8A

P932

Q42431459-9AF36E6F-F73A-4E24-AFC0-20F794D63669

P356

20734735.006316

P1433

P1476

Targeted therapies for lung cancer: how did the game begin?

@en

P2093

Ioannis Psallidas

http://www.w3.org/2001/XMLSchema#string

Nikolaos I Kanellakis

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody.

ALK inhibitors in the treatment of advanced NSCLC.

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.

Cancer: Drug for an 'undruggable' protein.

P304

177-179

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1183/20734735.006316

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27408637

http://www.w3.org/2001/XMLSchema#string

P932

4933615

http://www.w3.org/2001/XMLSchema#string